Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

VIGL

Vigil Neuroscience (VIGL)

Vigil Neuroscience Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VIGL
DateTimeSourceHeadlineSymbolCompany
05/08/20246:40AMGlobeNewswire Inc.Vigil Neuroscience to Present at The Citizens JMP Life Sciences ConferenceNASDAQ:VIGLVigil Neuroscience Inc
05/07/20244:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
05/07/20244:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
05/07/20244:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
05/07/20244:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
05/07/20243:35PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIGLVigil Neuroscience Inc
05/07/20243:20PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
05/07/20243:05PMGlobeNewswire Inc.Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
04/17/20243:05PMGlobeNewswire Inc.Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
03/26/20246:05AMGlobeNewswire Inc.Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
03/20/20246:05AMGlobeNewswire Inc.Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical OfficerNASDAQ:VIGLVigil Neuroscience Inc
03/13/20246:05AMGlobeNewswire Inc.Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
03/12/20246:05AMGlobeNewswire Inc.Vigil Neuroscience to Present at Stifel 2024 Virtual CNS DaysNASDAQ:VIGLVigil Neuroscience Inc
03/06/20243:25PMGlobeNewswire Inc.Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024NASDAQ:VIGLVigil Neuroscience Inc
03/01/20245:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
03/01/20244:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
02/29/20243:05PMGlobeNewswire Inc.Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024NASDAQ:VIGLVigil Neuroscience Inc
02/14/202410:33AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VIGLVigil Neuroscience Inc
02/07/20243:05PMGlobeNewswire Inc.Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:VIGLVigil Neuroscience Inc
01/11/20249:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
01/03/20243:30PMGlobeNewswire Inc.Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 MilestonesNASDAQ:VIGLVigil Neuroscience Inc
11/22/20233:05PMGlobeNewswire Inc.Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx ConferenceNASDAQ:VIGLVigil Neuroscience Inc
11/16/20233:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
11/16/20233:05PMGlobeNewswire Inc.Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATENASDAQ:VIGLVigil Neuroscience Inc
11/07/20236:30AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIGLVigil Neuroscience Inc
11/07/20236:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
11/07/20236:05AMGlobeNewswire Inc.Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
10/17/20236:05AMGlobeNewswire Inc.Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s DiseaseNASDAQ:VIGLVigil Neuroscience Inc
10/12/20233:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
10/05/20233:01PMGlobeNewswire Inc.Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro SummitNASDAQ:VIGLVigil Neuroscience Inc
 Showing the most relevant articles for your search:NASDAQ:VIGL

Your Recent History

Delayed Upgrade Clock